Biocartis

Bellen Routebeschrijving Website Contact opnemen met de praktijk

Biocartis Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idyllaโ„ข Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Companyโ€™s proprietary MDx Idyllaโ„ข platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idyllaโ„ข addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

06/10/2026

๐ŸŽฏ ๐‚๐จ๐ฆ๐ฉ๐ซ๐ž๐ก๐ž๐ง๐ฌ๐ข๐ฏ๐ž ๐›๐ข๐จ๐ฆ๐š๐ซ๐ค๐ž๐ซ ๐ญ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐ข๐ง ๐‚๐‘๐‚: ๐ˆ๐๐ฒ๐ฅ๐ฅ๐šโ„ข ๐ข๐ฌ ๐š๐ฅ๐ฅ ๐ฒ๐จ๐ฎ ๐ง๐ž๐ž๐

โœ”๏ธ Detection of all actionable KRAS, NRAS and BRAF mutations
โœ”๏ธ Idyllaโ„ข CDx MSI Test as Companion Diagnostic for nivolumab + ipilimumab
โœ”๏ธ Standardized result report in only 2.5 hours
โœ”๏ธ Fully automated molecular walk-away system for on-demand testing
โœ”๏ธ Directly from FFPE with < 3 min. HoT
โœ”๏ธ > 96% OPA for KRAS, NRAS, BRAF versus state-of-the-art methods

๐‹๐ž๐š๐ซ๐ง ๐ฆ๐จ๐ซ๐ž ๐Ÿ‘‰ https://www.biocartis.com/en/oncology/for-oncologists/idylla-for-colorectal-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0610_idylla-for-colorectal-cancer


The content of this post is only applicable to Idyllaโ„ข CDx MSI Test, which is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and approved in the US under P250005, and Idyllaโ„ข NRAS-BRAF & KRAS Mutation Tests, which are CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC, CE-IVD certification under IVDR is in progress. Idyllaโ„ข NRAS-BRAF & KRAS Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures in the US.

๐Ž๐œ๐ญ๐จ๐›๐ž๐ซ ๐ข๐ฌ ๐๐ซ๐ž๐š๐ฌ๐ญ ๐‚๐š๐ง๐œ๐ž๐ซ ๐€๐ฐ๐š๐ซ๐ž๐ง๐ž๐ฌ๐ฌ ๐Œ๐จ๐ง๐ญ๐ก, an annual campaign to raise awareness about the impact of breast cancer. Aware...
01/10/2026

๐Ž๐œ๐ญ๐จ๐›๐ž๐ซ ๐ข๐ฌ ๐๐ซ๐ž๐š๐ฌ๐ญ ๐‚๐š๐ง๐œ๐ž๐ซ ๐€๐ฐ๐š๐ซ๐ž๐ง๐ž๐ฌ๐ฌ ๐Œ๐จ๐ง๐ญ๐ก, an annual campaign to raise awareness about the impact of breast cancer.
Awareness is the first step in the battle against Cancer. Together we rise ๐Ÿ™Œโค๏ธ

๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ ๐จ๐ฎ๐ซ ๐๐ซ๐ž๐š๐ฌ๐ญ ๐‚๐š๐ง๐œ๐ž๐ซ ๐€๐ฌ๐ฌ๐š๐ฒ ๐๐จ๐ซ๐ญ๐Ÿ๐จ๐ฅ๐ข๐จ*: https://www.biocartis.com/en/breast-cancer-assay-portfolio?utm_source=facebook&utm_medium=social&utm_campaign=0110_breast-cancer-assay-portfolio

*For Research Use Only (RUO), not for use in diagnostic procedures.

The Biocartis team is at ๐—ฆ๐—˜๐—ข๐— ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ in Madrid, Spain!๐Ÿ˜ƒThis year marks the ๐Ÿฑ๐Ÿฌ๐˜๐—ต ๐—ฎ๐—ป๐—ป๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜€๐—ฎ๐—ฟ๐˜† ๐—ผ๐—ณ ๐—ฆ๐—˜๐—ข๐— , celebrating five decad...
30/09/2026

The Biocartis team is at ๐—ฆ๐—˜๐—ข๐— ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ in Madrid, Spain!๐Ÿ˜ƒ

This year marks the ๐Ÿฑ๐Ÿฌ๐˜๐—ต ๐—ฎ๐—ป๐—ป๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜€๐—ฎ๐—ฟ๐˜† ๐—ผ๐—ณ ๐—ฆ๐—˜๐—ข๐— , celebrating five decades of progress and innovation in medical oncology. Congratulations to SEOM on this remarkable milestone! ๐ŸŽ‰

Weโ€™re pleased to be part of this important meeting and look forward to connecting with colleagues, exchanging insights, and discussing the latest developments in oncology.

๐—”๐—ฟ๐—ฒ ๐˜†๐—ผ๐˜‚ ๐—ฎ๐˜๐˜๐—ฒ๐—ป๐—ฑ๐—ถ๐—ป๐—ด ๐—ฆ๐—˜๐—ข๐— ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ ๐˜๐—ผ๐—ผ? Weโ€™d love to connect! Reach out to Maite, Claudio, or Ester for a chat ๐Ÿ—จ๏ธ

29/09/2026

๐Ÿ’ก๐—›๐—ผ๐˜„ ๐—บ๐˜‚๐—ฐ๐—ต ๐—ฑ๐—ถ๐—ณ๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ฐ๐—ฎ๐—ป ๐—ณ๐—ฎ๐˜€๐˜, ๐—ฎ๐—ฐ๐—ฐ๐˜‚๐—ฟ๐—ฎ๐˜๐—ฒ ๐—ฏ๐—ถ๐—ผ๐—บ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐—ฟ ๐˜๐—ฒ๐˜€๐˜๐—ถ๐—ป๐—ด ๐—บ๐—ฎ๐—ธ๐—ฒ ๐˜๐—ผ ๐—ณ๐—ถ๐—ฟ๐˜€๐˜-๐—น๐—ถ๐—ป๐—ฒ ๐˜๐—ฟ๐—ฒ๐—ฎ๐˜๐—บ๐—ฒ๐—ป๐˜ ๐—ฑ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป๐˜€?
Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds, UK) explores this question in our on-demand webinar, highlighting why reliable MSI testing remains critical for identifying the right patients for immunotherapy.

๐—” ๐—ธ๐—ฒ๐˜† ๐˜๐—ฎ๐—ธ๐—ฒ๐—ฎ๐˜„๐—ฎ๐˜†: "๐˜๐˜ฏ ๐˜ต๐˜ฉ๐˜ฆ ๐˜Š๐˜ฉ๐˜ฆ๐˜ค๐˜ฌ๐˜”๐˜ข๐˜ต๐˜ฆ 8๐˜๐˜ž ๐˜ต๐˜ณ๐˜ช๐˜ข๐˜ญ, 17% ๐˜ฐ๐˜ง ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต๐˜ด ๐˜ค๐˜ญ๐˜ข๐˜ด๐˜ด๐˜ช๐˜ง๐˜ช๐˜ฆ๐˜ฅ ๐˜ข๐˜ด ๐˜ฅ๐˜”๐˜”๐˜™/๐˜”๐˜š๐˜-๐˜ ๐˜ฃ๐˜บ ๐˜ญ๐˜ฐ๐˜ค๐˜ข๐˜ญ ๐˜ต๐˜ฆ๐˜ด๐˜ต๐˜ช๐˜ฏ๐˜จ ๐˜ธ๐˜ฆ๐˜ณ๐˜ฆ ๐˜ณ๐˜ฆ๐˜ค๐˜ญ๐˜ข๐˜ด๐˜ด๐˜ช๐˜ง๐˜ช๐˜ฆ๐˜ฅ ๐˜ข๐˜ด ๐˜”๐˜š๐˜š ๐˜ฐ๐˜ฏ ๐˜ค๐˜ฆ๐˜ฏ๐˜ต๐˜ณ๐˜ข๐˜ญ ๐˜ณ๐˜ฆ๐˜ต๐˜ฆ๐˜ด๐˜ต๐˜ช๐˜ฏ๐˜จ ๐˜ฃ๐˜บ ๐˜๐˜ฅ๐˜บ๐˜ญ๐˜ญ๐˜ขโ„ข. ๐˜‰๐˜ถ๐˜ต ๐˜ธ๐˜ฉ๐˜ข๐˜ต ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ฆ๐˜ณ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ ๐˜ฅ๐˜ช๐˜ฅ ๐˜ต๐˜ฉ๐˜ข๐˜ต ๐˜ฎ๐˜ข๐˜ฌ๐˜ฆ ๐˜ต๐˜ฐ ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต๐˜ด? ๐˜ž๐˜ฉ๐˜ฆ๐˜ฏ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ข๐˜ฏ๐˜ข๐˜ญ๐˜บ๐˜ด๐˜ช๐˜ด ๐˜ธ๐˜ข๐˜ด ๐˜ณ๐˜ฆ๐˜ง๐˜ช๐˜ฏ๐˜ฆ๐˜ฅ ๐˜ต๐˜ฐ ๐˜ต๐˜ณ๐˜ถ๐˜ญ๐˜บ ๐˜”๐˜š๐˜-๐˜ ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต๐˜ด, ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฐ๐˜ฃ๐˜ซ๐˜ฆ๐˜ค๐˜ต๐˜ช๐˜ท๐˜ฆ ๐˜ณ๐˜ฆ๐˜ด๐˜ฑ๐˜ฐ๐˜ฏ๐˜ด๐˜ฆ ๐˜ณ๐˜ข๐˜ต๐˜ฆ ๐˜ธ๐˜ข๐˜ด ๐˜ด๐˜ช๐˜จ๐˜ฏ๐˜ช๐˜ง๐˜ช๐˜ค๐˜ข๐˜ฏ๐˜ต๐˜ญ๐˜บ ๐˜ฉ๐˜ช๐˜จ๐˜ฉ๐˜ฆ๐˜ณ. ๐˜›๐˜ฉ๐˜ช๐˜ด ๐˜ต๐˜ฆ๐˜ญ๐˜ญ๐˜ด ๐˜ถ๐˜ด ๐˜ธ๐˜ฆ ๐˜ข๐˜ณ๐˜ฆ ๐˜ฏ๐˜ฐ๐˜ต ๐˜บ๐˜ฆ๐˜ต ๐˜ธ๐˜ฉ๐˜ฆ๐˜ณ๐˜ฆ ๐˜ธ๐˜ฆ ๐˜ฏ๐˜ฆ๐˜ฆ๐˜ฅ ๐˜ต๐˜ฐ ๐˜ฃ๐˜ฆ ๐˜ธ๐˜ช๐˜ต๐˜ฉ ๐˜ข๐˜ค๐˜ค๐˜ถ๐˜ณ๐˜ข๐˜ต๐˜ฆ ๐˜ต๐˜ฆ๐˜ด๐˜ต๐˜ช๐˜ฏ๐˜จ, ๐˜ข๐˜ฏ๐˜ฅ ๐˜ต๐˜ฉ๐˜ข๐˜ต ๐˜จ๐˜ข๐˜ฑ ๐˜ฉ๐˜ข๐˜ด ๐˜ณ๐˜ฆ๐˜ข๐˜ญ ๐˜ค๐˜ฐ๐˜ฏ๐˜ด๐˜ฆ๐˜ฒ๐˜ถ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ๐˜ด ๐˜ง๐˜ฐ๐˜ณ ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต๐˜ด ๐˜ข๐˜ฏ๐˜ฅ ๐˜ต๐˜ฉ๐˜ฆ๐˜ช๐˜ณ ๐˜ง๐˜ช๐˜ณ๐˜ด๐˜ต-๐˜ญ๐˜ช๐˜ฏ๐˜ฆ ๐˜ต๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต ๐˜ฅ๐˜ฆ๐˜ค๐˜ช๐˜ด๐˜ช๐˜ฐ๐˜ฏ๐˜ด."

In the webinar, Professor Seligmann also explores:
โœ”๏ธ Updates to the ESMO mCRC guidelines
โœ”๏ธ Dual IHC/molecular testing for immunotherapy eligibility
โœ”๏ธ Emerging biomarker testing strategies in early-stage disease

๐ŸŽฅ ๐—ช๐—ฎ๐˜๐—ฐ๐—ต ๐˜๐—ต๐—ฒ ๐˜„๐—ฒ๐—ฏ๐—ถ๐—ป๐—ฎ๐—ฟ: https://www.biocartis.com/en/oncology/on-demand-webinars/crc-testing-in-2026-whats-new-whats-next-an-oncologists-perspective-on?utm_source=facebook&utm_medium=social&utm_campaign=2909_crc-testing-in-2026


Idyllaโ„ข CDx MSI Test (A0220/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and approved in the US under P250005.

28/09/2026

The new Belgian healthcare campaign โ€œ๐—ง๐—ฟ๐—ฒ๐—ฎ๐˜๐—บ๐—ฒ๐—ป๐˜๐˜€ & ๐—ฃ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜๐˜€โ€ shines a light on how innovation is transforming cancer care, including through precision medicine and faster diagnostics ๐Ÿงฌ

In precision oncology, ๐—ฒ๐˜ƒ๐—ฒ๐—ฟ๐˜† ๐˜๐˜‚๐—บ๐—ผ๐—ฟ ๐—ถ๐˜€ ๐—ฑ๐—ถ๐—ณ๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐˜. Understanding its ๐—บ๐—ผ๐—น๐—ฒ๐—ฐ๐˜‚๐—น๐—ฎ๐—ฟ ๐—ฝ๐—ฟ๐—ผ๐—ณ๐—ถ๐—น๐—ฒ can help identify the most ๐—ฎ๐—ฝ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ฟ๐—ถ๐—ฎ๐˜๐—ฒ ๐˜๐—ฟ๐—ฒ๐—ฎ๐˜๐—บ๐—ฒ๐—ป๐˜ for each patient. And because treatment decisions can be time-sensitive, getting this information ๐—พ๐˜‚๐—ถ๐—ฐ๐—ธ๐—น๐˜† matters. As Dr. W. Michael Korn, MD (Chief Medical and Scientific Officer at Biocartis) puts it: โ€œ๐˜Œ๐˜ท๐˜ฆ๐˜ณ๐˜บ ๐˜ฅ๐˜ข๐˜บ ๐˜ญ๐˜ฐ๐˜ด๐˜ต ๐˜ข๐˜ง๐˜ต๐˜ฆ๐˜ณ ๐˜ฅ๐˜ช๐˜ข๐˜จ๐˜ฏ๐˜ฐ๐˜ด๐˜ช๐˜ด ๐˜ฑ๐˜ถ๐˜ต๐˜ด ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต ๐˜ข๐˜ต ๐˜ณ๐˜ช๐˜ด๐˜ฌ ๐˜ฐ๐˜ง ๐˜ต๐˜ฉ๐˜ฆ๐˜ช๐˜ณ ๐˜ค๐˜ฐ๐˜ฏ๐˜ฅ๐˜ช๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ฅ๐˜ฆ๐˜ต๐˜ฆ๐˜ณ๐˜ช๐˜ฐ๐˜ณ๐˜ข๐˜ต๐˜ช๐˜ฏ๐˜จ ๐˜ต๐˜ฐ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฑ๐˜ฐ๐˜ช๐˜ฏ๐˜ต ๐˜ธ๐˜ฉ๐˜ฆ๐˜ณ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ๐˜บ ๐˜ค๐˜ข๐˜ฏ ๐˜ฏ๐˜ฐ ๐˜ญ๐˜ฐ๐˜ฏ๐˜จ๐˜ฆ๐˜ณ ๐˜ณ๐˜ฆ๐˜ค๐˜ฆ๐˜ช๐˜ท๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ข๐˜ฑ๐˜ฑ๐˜ณ๐˜ฐ๐˜ฑ๐˜ณ๐˜ช๐˜ข๐˜ต๐˜ฆ ๐˜ต๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต. [...] ๐˜›๐˜ฉ๐˜ฆ ๐˜ด๐˜ฐ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ณ ๐˜ธ๐˜ฆ ๐˜ถ๐˜ฏ๐˜ฅ๐˜ฆ๐˜ณ๐˜ด๐˜ต๐˜ข๐˜ฏ๐˜ฅ ๐˜ธ๐˜ฉ๐˜ข๐˜ต ๐˜ช๐˜ด ๐˜ฉ๐˜ข๐˜ฑ๐˜ฑ๐˜ฆ๐˜ฏ๐˜ช๐˜ฏ๐˜จ ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜ฅ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ต๐˜ถ๐˜ฎ๐˜ฐ๐˜ณ, ๐˜ต๐˜ฉ๐˜ฆ ๐˜ด๐˜ฐ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ณ ๐˜ธ๐˜ฆ ๐˜ค๐˜ข๐˜ฏ ๐˜ด๐˜ต๐˜ข๐˜ณ๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต. ๐™„๐™ฉ ๐™ž๐™จ ๐™ฉ๐™ง๐™ช๐™ก๐™ฎ ๐™–๐™—๐™ค๐™ช๐™ฉ ๐™จ๐™–๐™ซ๐™ž๐™ฃ๐™œ ๐™ก๐™ž๐™ซ๐™š๐™จ.โ€

With ๐—œ๐—ฑ๐˜†๐—น๐—น๐—ฎโ„ข, molecular biomarker results can be delivered in only 3 hours, helping professionals access actionable information sooner and supporting timely treatment decisions. ๐Ÿ’ก๐—•๐—ฒ๐—ฐ๐—ฎ๐˜‚๐˜€๐—ฒ ๐—ถ๐—ป ๐—ฐ๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ ๐—ฐ๐—ฎ๐—ฟ๐—ฒ, ๐˜๐—ต๐—ฒ ๐—ฟ๐—ถ๐—ด๐—ต๐˜ ๐—ถ๐—ป๐—ณ๐—ผ๐—ฟ๐—บ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฎ๐˜ ๐˜๐—ต๐—ฒ ๐—ฟ๐—ถ๐—ด๐—ต๐˜ ๐˜๐—ถ๐—บ๐—ฒ ๐—ฐ๐—ฎ๐—ป ๐—บ๐—ฎ๐—ธ๐—ฒ ๐—ฎ๐—น๐—น ๐˜๐—ต๐—ฒ ๐—ฑ๐—ถ๐—ณ๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐˜๐—ผ ๐˜๐—ต๐—ฒ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜๐˜€.

๐Ÿ‘‰ ๐—ฅ๐—ฒ๐—ฎ๐—ฑ ๐˜๐—ต๐—ฒ ๐—ณ๐˜‚๐—น๐—น ๐—ฎ๐—ฟ๐˜๐—ถ๐—ฐ๐—น๐—ฒ: https://fr.planet-health.be/traitements-patients/cancer-idylla-ce-laboratoire-miniature-qui-livre-ses-resultats-en-quelques-heures/

๐Ÿ‘‰ ๐——๐—ถ๐˜€๐—ฐ๐—ผ๐˜ƒ๐—ฒ๐—ฟ ๐˜„๐—ต๐—ฎ๐˜ ๐—œ๐—ฑ๐˜†๐—น๐—น๐—ฎโ„ข ๐—ฐ๐—ฎ๐—ป ๐—บ๐—ฒ๐—ฎ๐—ป ๐—ณ๐—ผ๐—ฟ ๐˜†๐—ผ๐˜‚ ๐—ฎ๐—ป๐—ฑ ๐˜†๐—ผ๐˜‚๐—ฟ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜๐˜€: https://www.biocartis.com/en/meet-idylla

๐Ÿ™‹โ€โ™‚๏ธ๐—ช๐—ฒ'๐—ฟ๐—ฒ ๐—ฎ๐˜ ๐—›๐—ฒ๐—ฟ๐—ฏ๐˜€๐˜๐˜๐—ฎ๐—ด๐˜‚๐—ป๐—ด ๐—ข๐—š๐—ฃ๐—”๐—ง๐—› ๐—ถ๐—ป ๐—Ÿ๐—ถ๐—ป๐˜‡, ๐—”๐˜‚๐˜€๐˜๐—ฟ๐—ถ๐—ฎ!Visit Dr. Manfred and Thomas to discover how the ๐—œ๐—ฑ๐˜†๐—น๐—น๐—ฎโ„ข ๐—ฃ๐—น๐—ฎ๐˜๐—ณ๐—ผ๐—ฟ๐—บ can ...
25/09/2026

๐Ÿ™‹โ€โ™‚๏ธ๐—ช๐—ฒ'๐—ฟ๐—ฒ ๐—ฎ๐˜ ๐—›๐—ฒ๐—ฟ๐—ฏ๐˜€๐˜๐˜๐—ฎ๐—ด๐˜‚๐—ป๐—ด ๐—ข๐—š๐—ฃ๐—”๐—ง๐—› ๐—ถ๐—ป ๐—Ÿ๐—ถ๐—ป๐˜‡, ๐—”๐˜‚๐˜€๐˜๐—ฟ๐—ถ๐—ฎ!

Visit Dr. Manfred and Thomas to discover how the ๐—œ๐—ฑ๐˜†๐—น๐—น๐—ฎโ„ข ๐—ฃ๐—น๐—ฎ๐˜๐—ณ๐—ผ๐—ฟ๐—บ can deliver molecular biomarker results in ๐—ผ๐—ป๐—น๐˜† ๐Ÿฏ ๐—ต๐—ผ๐˜‚๐—ฟ๐˜€โฑ๏ธ They're eager to show you...

๐—Ÿ๐—ฒ๐—ฎ๐—ฟ๐—ป ๐—บ๐—ผ๐—ฟ๐—ฒ ๐Ÿ‘‰ https://www.biocartis.com/en/meet-idylla

21/09/2026

๐Ÿซ ๐…๐š๐ฌ๐ญ ๐ญ๐ซ๐š๐œ๐ค ๐š๐œ๐ญ๐ข๐จ๐ง๐š๐›๐ฅ๐ž ๐›๐ข๐จ๐ฆ๐š๐ซ๐ค๐ž๐ซ ๐ญ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐ข๐ง ๐๐’๐‚๐‹๐‚: ๐“๐‡๐ˆ๐๐Š ๐ˆ๐ƒ๐˜๐‹๐‹๐€โ„ข
*
โœ”๏ธ Detection of all actionable EGFR, ALK, ROS1, RET, METex14 and NTRK* mutations
โœ”๏ธ Idyllaโ„ข EGFR Mutation Test as Companion Diagnostic for multiple TKIs**
โœ”๏ธ Standardized result report in only 3 hours
โœ”๏ธ Fully automated molecular walk-away system for on-demand testing
โœ”๏ธ Directly from FFPE with < 3 min. HoT
โœ”๏ธ > 96% OPA for EGFR, ALK, ROS1, RET, MET versus state-of-the-art methods

๐‹๐ž๐š๐ซ๐ง ๐ฆ๐จ๐ซ๐ž ๐Ÿ‘‰ https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=2109_idylla-for-lung-cancer


* NTRK is covered by Idyllaโ„ข GeneFusion Assay, which is for Research Use Only (RUO), not for use in diagnostic procedures.
** Gefitinib, erlotinib and osimertinib.
The content of this post is only applicable to Idyllaโ„ข EGFR Mutation Test (A0270/6), which is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and Idyllaโ„ข GeneFusion Panel (A0120/6) is CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC, CE-IVD certification under IVDR is in progress. Both Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

17/09/2026

๐ŸŒ On ๐–๐จ๐ซ๐ฅ๐ ๐๐š๐ญ๐ข๐ž๐ง๐ญ ๐’๐š๐Ÿ๐ž๐ญ๐ฒ ๐ƒ๐š๐ฒ, we recognize the vital role molecular biomarker testing plays in guiding treatment decisions for cancer patients.

The Idyllaโ„ข Platform delivers fully automated molecular biomarker results in only 3 hours, providing clinicians with actionable results in time to support treatment selection.

๐๐ž๐œ๐š๐ฎ๐ฌ๐ž ๐ข๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ข๐ง๐  ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ ๐ฌ๐š๐Ÿ๐ž๐ญ๐ฒ ๐ข๐ฌ๐ง'๐ญ ๐ฃ๐ฎ๐ฌ๐ญ ๐š๐›๐จ๐ฎ๐ญ ๐ซ๐ž๐๐ฎ๐œ๐ข๐ง๐  ๐๐ž๐ฅ๐š๐ฒ๐ฌ, ๐ข๐ญ'๐ฌ ๐š๐›๐จ๐ฎ๐ญ ๐ ๐ข๐ฏ๐ข๐ง๐  ๐œ๐ฅ๐ข๐ง๐ข๐œ๐ข๐š๐ง๐ฌ ๐ญ๐ก๐ž ๐œ๐จ๐ง๐Ÿ๐ข๐๐ž๐ง๐œ๐ž ๐ญ๐จ ๐ข๐๐ž๐ง๐ญ๐ข๐Ÿ๐ฒ ๐ญ๐ก๐ž ๐ฆ๐จ๐ฌ๐ญ ๐š๐ฉ๐ฉ๐ซ๐จ๐ฉ๐ซ๐ข๐š๐ญ๐ž ๐ญ๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Ÿ๐จ๐ซ ๐ž๐ฅ๐ข๐ ๐ข๐›๐ฅ๐ž ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ, so they can start the right treatment at the right time ๐Ÿ’ก

๐‹๐ž๐š๐ซ๐ง ๐ฆ๐จ๐ซ๐ž ๐Ÿ‘‰ https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1709_meet-idylla

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact Opnemen Met De Praktijk

Stuur een bericht naar Biocartis:

Snelkoppelingen

Delen

Categorie